PharmaEssentia Signs Deal for Puerto Rico Plant by 2027

PharmaEssentia Signs Investment Agreement for Puerto Rico Manufacturing Facility

Taiwan-based global biopharmaceutical company PharmaEssentia Corporation (TWSE: 6446) signed a formal investment agreement on Thursday, March 26, 2026, for the development of a new manufacturing facility in Toa Baja, Puerto Rico, marking a significant milestone in the company's strategy to establish a dual-site manufacturing network between Taiwan and the United States. The signing ceremony, held in Puerto Rico, was attended by Governor Jenniffer González Colón, Secretary of Economic Development and Commerce Sebastián Negrón Reichard, US Department of Commerce Director for Puerto Rico José Burgos, Taipei Economic and Cultural Office Director General Chi Yu Chou, and Invest Puerto Rico CEO Ella Woger-Nieves, among other officials.

Strategic Manufacturing Expansion

The Puerto Rico facility is designed to the same quality standards as PharmaEssentia's existing manufacturing site in Taichung, Taiwan, while optimising production efficiency and diversifying supply chain risk. Personnel from the new facility will undergo intensive training at the Taichung site as part of a knowledge transfer programme. PharmaEssentia is planning to begin operations in 2027, pending receipt of all required regulatory approvals. The company's primary product manufactured at the facility will be BESREMi® (ropeginterferon alfa-2b-njft), an FDA-approved biologic for the treatment of adults with polycythemia vera (PV), which has received regulatory approval in over 40 countries including from the European Medicines Agency in 2019 and FDA in 2021.

Bilateral Significance and Economic Impact

TECO Miami Director General Chi Yu Chou called the investment "a clear demonstration of the strengthening economic ties between Taiwan and the United States," while Governor González Colón said the facility "reaffirms Puerto Rico's position as a reliable and competitive US jurisdiction for advanced biopharmaceutical manufacturing." Founded in 2003 by a team of Taiwanese-American scientists, PharmaEssentia today operates in the US, Japan, China, and Korea. Its Puerto Rico facility represents a landmark expansion of the island's already globally significant pharmaceutical manufacturing sector.